Allergy Therapeutics submits Swiss MAA for grass allergy vaccine
This article was originally published in Scrip
Executive Summary
UK-based Allergy Therapeutics has submitted a marketing authorisation application (MAA) to the Swiss regulatory authority, Swissmedic, for its grass allergy vaccine, Grass MATA MPL, furthering its ambition to become one of the top three allergy immunotherapy companies globally.